MPXV DNA kinetics in bloodstream and other body fluids samples.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      DNA, Viral*/genetics ; Viral Load* ; Body Fluids*/virology ; Monkeypox virus*/genetics ; Monkeypox virus*/isolation & purification; Humans ; Male ; Kinetics ; Semen/virology ; Mpox (monkeypox)/virology ; Mpox (monkeypox)/epidemiology ; Mpox (monkeypox)/diagnosis ; Saliva/virology ; Female ; Adult ; Virus Shedding ; Middle Aged
    • Abstract:
      Since spring 2022, the global epidemiology of the monkeypox virus (MPXV) has changed. The unprecedented increase of human clade II MPXV cases worldwide heightened concerns about this emerging zoonotic disease. We analysed the positivity rates, viral loads, infectiousness, and persistence of MPXV DNA for up to 4 months in several biological samples from 89 MPXV-confirmed cases. Our data showed that viral loads and positivity rates were higher during the first two weeks of symptoms for all sample types. Amongst no-skin-samples, respiratory specimens showed higher MPXV DNA levels and median time until viral clearance, suggesting their usefulness in supporting MPXV diagnosis, investigating asymptomatic patients, and monitoring viral shedding. Infectious virus was cultured from respiratory samples, semen, and stools, with high viral loads and collected within the first 10 days. Notably, only one saliva and one semen were found positive for viral DNA after 71 and 31 days from symptoms, respectively. The focus on bloodstream samples showed the best testing sensitivity in plasma, reporting the overall highest MPXV DNA detection rate and viral loads during the 3-week follow-up as compared to serum and whole-blood. The data here presented can be useful for MPXV diagnostics and a better understanding of the potential alternative routes of its onward transmission.
      (© 2024. The Author(s).)
    • References:
      Viruses. 2023 Jun 17;15(6):. (PMID: 37376686)
      Emerg Infect Dis. 2021;27(7):1821-1830. (PMID: 34152951)
      N Engl J Med. 2022 Aug 25;387(8):679-691. (PMID: 35866746)
      Int J Infect Dis. 2023 May;130:48-51. (PMID: 36858309)
      Transplant Proc. 2023 Apr;55(3):667-671. (PMID: 36941151)
      J Infect. 2022 Dec;85(6):702-769. (PMID: 36265827)
      J Clin Virol. 2023 Apr;161:105421. (PMID: 36893717)
      Clin Microbiol Infect. 2023 Feb;29(2):233-239. (PMID: 36028090)
      Euro Surveill. 2022 Aug;27(33):. (PMID: 35983771)
      Euro Surveill. 2022 Jul;27(28):. (PMID: 35837964)
      J Travel Med. 2023 Sep 5;30(5):. (PMID: 37581603)
      Transfus Med. 2022 Dec;32(6):460-466. (PMID: 36134432)
      Transfus Med Rev. 2023 Oct;37(4):150769. (PMID: 37919210)
      Transfusion. 2023 Apr;63(4):690-695. (PMID: 36752042)
      Lancet Microbe. 2023 Jan;4(1):e21-e28. (PMID: 36436538)
      Lancet Infect Dis. 2023 Jan;23(1):74-80. (PMID: 36183707)
      J Clin Virol. 2023 Feb;159:105372. (PMID: 36608620)
      Emerg Infect Dis. 2024 Mar;30(3):603-605. (PMID: 38407395)
      Lancet Infect Dis. 2024 Feb;24(2):e127-e135. (PMID: 37778364)
      Viruses. 2023 Apr 30;15(5):. (PMID: 37243193)
      J Infect. 2023 Jul;87(1):54-56. (PMID: 37030631)
      Clin Infect Dis. 2023 Nov 17;77(10):1483-1484. (PMID: 37417243)
      Nat Med. 2022 Nov;28(11):2288-2292. (PMID: 35961373)
      J Virol Methods. 2010 Oct;169(1):223-7. (PMID: 20643162)
      Emerg Infect Dis. 2022 Oct;28(10):2074-2077. (PMID: 36148930)
      Travel Med Infect Dis. 2022 Nov-Dec;50:102459. (PMID: 36109000)
      Clin Infect Dis. 2007 Jul 15;45(2):181-6. (PMID: 17578776)
      Lancet Infect Dis. 2023 Apr;23(4):445-453. (PMID: 36521505)
      Travel Med Infect Dis. 2024 May-Jun;59:102698. (PMID: 38556220)
      iScience. 2023 Mar 17;26(3):106102. (PMID: 36748085)
      J Med Virol. 2023 May;95(5):e28791. (PMID: 37226579)
      Transplantation. 2022 Nov 1;106(11):e512-e513. (PMID: 35973036)
      J Clin Virol. 2022 Oct;155:105254. (PMID: 36057206)
      J Infect. 2022 Nov;85(5):573-607. (PMID: 35987391)
      J Infect. 2022 Oct;85(4):412-417. (PMID: 35830908)
      PLoS One. 2023 Jan 20;18(1):e0278862. (PMID: 36662705)
      Anal Bioanal Chem. 2018 Apr;410(10):2569-2583. (PMID: 29504082)
      Ann Intern Med. 2022 Oct;175(10):1491-1492. (PMID: 35969863)
    • Grant Information:
      871029 European-Virus-Archive-GLOBAL-871029; ISIDORe -101046133 European Union's Horizon Europe; Ricerca Corrente, Linea 1 Ministero della Salute
    • Accession Number:
      0 (DNA, Viral)
    • Publication Date:
      Date Created: 20240612 Date Completed: 20240612 Latest Revision: 20240615
    • Publication Date:
      20240615
    • Accession Number:
      PMC11169222
    • Accession Number:
      10.1038/s41598-024-63044-5
    • Accession Number:
      38866796